Managing Director & Senior Partner, Global Sector Leader, Biopharmaceuticals
Ulrik Schulze leads Boston Consulting Group’s biopharmaceuticals sector and is a member of the Health Care practice in Switzerland. He is a member of the firm’s Marketing, Sales & Pricing, Operations, Corporate Development, People & Organization, and Strategy practices.
Since joining BCG in 1997, Ulrik has worked intensively with clients in the pharmaceutical, biotechnology, medtech, and private-equity sectors in the US, Europe, and Asia. He has worked globally with management teams of leading global companies as well as ambitious emerging companies and private equity firms. His experience covers the full value chain from R&D and manufacturing to commercial, business development and capital market strategies.
Ulrik’s work has more recently focused on strategy development, M&A, post-merger integration as well as organizational and operational transformations. His experience in corporate strategy includes acquisitions, integrations, licensing, and alignment of strategy with value creation for shareholders.
Before joining BCG, Ulrik worked as a postdoctoral fellow in the chemical engineering and biology departments at the Massachusetts Institute of Technology.
AI is beginning to transform biologics discovery. Today between 50 and 60 AI-enabled biologics are in different stages of discovery, preclinical and clinical development. Advances in AI technology and algorithms suggest that this trend will continue to grow exponentially over time.
Our latest research shows that consumers are embracing alternative proteins and that protein transformation is one of the best tools available to combat the climate crisis.
Artificial intelligence-enabled drug discovery holds the promise of dramatically changing pharmaceutical R&D. By improving productivity, broadening molecular diversity, and improving chances of clinical success, AI-native companies are already making a mark on the industry.
Another pandemic is on the horizon—and in plain sight. Avoiding its full impact requires action now.
What challenges does the future hold for a fast-evolving sector that has undergone decades of change in the past 18 months?
Powerful new models are in the works, but effective implementation depends on building the right capabilities and enablers.
BCG’s latest survey on the impact of COVID-19 shows which changes in how doctors engage with the pharma industry will last beyond the pandemic.
The shift to alternative proteins based on plants, microorganisms, and animal cells is just beginning to pick up speed. The market will hit $290 billion by 2035.
The pandemic has transformed health care. Physicians expect long-term changes in how they interact with biopharma companies.
What happens when longstanding channels of interaction no longer function? Companies are fundamentally changing the way they support the delivery of health care.
In their response to COVID-19, pharma and medtech companies have been true to their purpose. They now face questions that go beyond addressing the virus itself.